S**+-methylmethionine | 13065-25-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: S**+-methylmethionine
• 英文别名: dimethyl-(3-amino-3-carboxy-propyl)-sulfonium hydroxide；Dimethyl-(3-amino-3-carboxy-propyl)-sulfoniumhydroxyd；DL-2-Amino-4-dimethylsulfonio-buttersaeure-hydroxyd；DL-Methionin-S-methohydroxyd；S-Methyl-DL-methioninsulfonium；S-Methylmethioninsulfenium；2-Azaniumyl-4-dimethylsulfoniobutanoate；2-azaniumyl-4-dimethylsulfoniobutanoate
• CAS: 13065-25-3
• 化学式: C₆H₁₄NO₂S
• 分子量: 164.249
• InChiKey: YDBYJHTYSHBBAU-UHFFFAOYSA-O

物化性质

• 物理描述：
  Solid
• 熔点：
  139°C(decomposition)

计算性质

• 辛醇/水分配系数(LogP)：
  -3
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  64.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  DL-谷氨酸 、 S**+-methylmethionine 、 zinc(II) chloride 以 乙醇 、 水 为溶剂， 以97%的产率得到S(+)-methylmethionine aquatrichlorozincate glutamine
  参考文献：
  名称：

  Akbarov, A. B.; Mutalibov, A. S., Journal of general chemistry of the USSR, 1990, vol. 60, p. 1691 - 1695

  摘要：

  DOI：

文献信息

• Prodrugs containing novel bio-cleavable linkers
  申请人：Satyam Apparao

  公开号：US20060046967A1

  公开（公告）日：2006-03-02

  The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I.

  本发明提供了公式(I)的化合物或其药用可接受的盐。本发明还提供了包含一个或多个公式I的化合物或其中间体以及一个或多个药用可接受的载体、车辆或稀释剂的药物组合物。本发明进一步提供了包括制备方法和使用方法在内的前药，包括释放一氧化氮的前药、双前药和相互前药，由公式I的化合物组成。
• [EN] NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS<br/>[FR] PROMÉDICAMENTS D'AGENTS THÉRAPEUTIQUES LIBÉRANT DE L'OXYDE NITRIQUE
  申请人：SATYAM APPARAO

  公开号：WO2014111957A1

  公开（公告）日：2014-07-24

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents wherein the drug or therapeutic agents contain at least one carboxylic acid group. The invention also relates to processes for the preparation of these nitric oxide releasing prodrugs, to pharmaceutical compositions containing them and to methods of using these prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其中所述药物或治疗剂至少含有一个羧酸基团。发明还涉及制备这些一氧化氮释放前药的方法，包含它们的药物组合物以及使用这些前药的方法。
• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• [EN] USE OF OXYGENATED CHOLESTEROL SULFATES FOR TREATING AT LEAST ONE OF INSULIN RESISTANCE, DIABETES, AND PREDIABETES<br/>[FR] UTILISATION DE SULFATES DE CHOLESTÉROL OXYGÉNÉS À DES FINS DE TRAITEMENT DE LA RÉSISTANCE À L'INSULINE ET/OU DU DIABÈTE ET/OU DU PRÉDIABÈTE
  申请人：DURECT CORP

  公开号：WO2021263185A1

  公开（公告）日：2021-12-30

  Aspects of the present disclosure include methods for treating at least one of insulin resistance, diabetes, and prediabetes, and, optionally, also non-alcoholic steatohepatitis (NASH). In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25- hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27- hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24- hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.

  本公开的方面包括用于治疗胰岛素抵抗、糖尿病和糖尿病前期以及可选地治疗非酒精性脂肪性肝病（NASH）的方法。在实施该方法时，向受试者施用至少一种选自25-羟基胆固醇-3-硫酸酯（25HC3S）、25-羟基胆固醇-二硫酸酯（25HCDS）、27-羟基胆固醇-3-硫酸酯（27HC3S）、27-羟基胆固醇-二硫酸酯（27HCDS）、24-羟基胆固醇-3-硫酸酯（24HC3S）、24-羟基胆固醇-二硫酸酯（24HCDS）和24,25-环氧胆固醇-3-硫酸酯或其盐的有效量化合物。
• [EN] ORGANIC NUTRIENT SALTS, METHODS OF PREPARATION AND USES<br/>[FR] SELS NUTRITIFS ORGANIQUES, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS
  申请人：BELLUS HEALTH INT LTD

  公开号：WO2010054485A1

  公开（公告）日：2010-05-20

  The current application relates to organic nutrient salts comprised of 3-amino-1-propanesulfonic acid (homotaurine) and an organic cationic component which contributes to the therapeutic and/or nutritional value of the salts. The application also relates to the method of preparing the organic nutrient salts and the use of the same as nutraceuticals for neuroprotection and for improving or protecting cognitive and memory functions.

  这项当前的申请涉及由3-氨基-1-丙磺酸（同牛磺酸）和一个有机阳离子组分组成的有机营养盐，该组分有助于盐的治疗和/或营养价值。该申请还涉及制备有机营养盐的方法以及将其用作神经保护的营养保健品，以改善或保护认知和记忆功能。